While my effective cost basis has declined with cash in the brokerage account, I currently own fewer shares, at higher price(s), and less than 50% of my previous ownership percentage.
Spec Bio is a perpetual cash raising Sector with unknown true deletion until a viable product. Anavex is not there yet. Will the outstanding share count remain below 120M by the time of approval? I think interesting question for the next 3-5 years.
Market Data 
Markets 
AI
